Bromodomain and extra-terminal (BET) inhibitors suppress super-enhancers and show cytotoxicity against multiple types of tumors. However, early clinical trials with BET inhibitors showed severe hematopoietic toxicities, highlighting the need for sensitive tumors and rational combination strategies to enhance their therapeutic potential. Here, we identified colon cancer-specific super-enhancers that were associated with multiple oncogenic pathways, including the mitogen-activated protein kinase (MAPK) signaling pathway.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rCNkph
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 4 January 2018 Source: European Journal of Radiology Author(s): Peiyao Zhang, Jing Wang, Qin Xu, Zhen...
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
Abstract Bone homeostasis is maintained by a balance between resorption of the bone matrix and its replacement by new bone. Osteoclasts p...
-
Abstract Continuous tooth replacement is common for tetrapods, but some groups of acrodont lepidosaurs have lost the ability to replace th...
-
from Imaging via alkiviadis.1961 on Inoreader http://ift.tt/2God5y1
-
ACS Nano DOI: 10.1021/acsnano.6b07537 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2i580k9 via...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου